Literature DB >> 8631034

Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth.

O Melnyk1, M A Shuman, K J Kim.   

Abstract

Tumor growth is dependent on new blood vessel formation. Inhibition of vascular endothelial growth factor (VEGF), an endothelial cell mitogen and angiogenic factor secreted by a variety of tumors and tumor cell lines, is sufficient to inhibit primary tumor growth. In the present study, we examined the effect of inhibiting VEGF on tumor cell micrometastasis. A transfectant of A431 (a human epidermoid carcinoma cell line) expressing chloramphenicol acetyltransferase (CAT) was injected s.c. into severe combined immunodeficiency (scid) mice, which were then sacrificed after 6 weeks. The presence of A431 metastases at distant sites was demonstrated by detection of CAT activity in whole-organ lysates. Treatment of animals with VEGF-neutralizing antibodies not only inhibited primary tumor growth but also suppressed metastases, as determined by CAT activity in organ lysates. In experiments to determine the mechanism by which anti-VEGF antibody inhibited metastasis, control animals were sacrificed when their tumors had reached the same size as tumors in VEGF antibody-treated animals. Metastases were uniformly present in these control animals. These findings show that inhibition of VEGF alone is sufficient to prevent tumor growth and dissemination in vivo. The inhibitory effect on metastases appears to be distinct from that on primary tumor growth.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8631034

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis.

Authors:  O Gallo; A Franchi; L Magnelli; I Sardi; A Vannacci; V Boddi; V Chiarugi; E Masini
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

2.  A hybrid model for three-dimensional simulations of sprouting angiogenesis.

Authors:  Florian Milde; Michael Bergdorf; Petros Koumoutsakos
Journal:  Biophys J       Date:  2008-06-27       Impact factor: 4.033

Review 3.  Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.

Authors:  John H Strickler; Herbert I Hurwitz
Journal:  Oncologist       Date:  2012-04-03

4.  Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis.

Authors:  M Streit; L Riccardi; P Velasco; L F Brown; T Hawighorst; P Bornstein; M Detmar
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

5.  Expression of vascular endothelial growth factor in hepatocellular carcinoma and its relationship to tumor growth and metastasis.

Authors:  S Zheng; Z Wu; Y Ruan; J Tang
Journal:  J Tongji Med Univ       Date:  1998

6.  Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody.

Authors:  F Yuan; Y Chen; M Dellian; N Safabakhsh; N Ferrara; R K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

Review 7.  Response of tumour cells to hypoxia: role of p53 and NFkB.

Authors:  J A Royds; S K Dower; E E Qwarnstrom; C E Lewis
Journal:  Mol Pathol       Date:  1998-04

8.  Targeted therapies in the management of colorectal carcinoma: role of bevacizumab.

Authors:  Ajithkumar Puthillath; Anush Patel; Marwan G Fakih
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

9.  Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery.

Authors:  Anastasios J Karayiannakis; Konstantinos N Syrigos; Alexandros Polychronidis; Andrew Zbar; Gregory Kouraklis; Constantinos Simopoulos; Gabriel Karatzas
Journal:  Ann Surg       Date:  2002-07       Impact factor: 12.969

10.  Inhibition of epidermoid carcinoma A431 cell growth and angiogenesis in nude mice by early and late treatment with a novel dextran derivative.

Authors:  M Di Benedetto; A Starzec; R Vassy; G Y Perret; M Crépin; M Kraemer
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.